Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine
MK-8591-013
Phase 2 small_molecule active
Quick answer
Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine for HIV-1 Infection is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- HIV-1 Infection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active